ATEX Anterix Inc. Insider Trading

Chief Reg & Comm Officer Christopher Guttman-McCabe sold 91,437 shares for $7.5M at blended avg $82.46

Christopher Guttman-McCabe executed 4 separate sales on 2026-06-15, totaling 91,437 shares for $7,539,883.84 at prices ranging from $81.32 to $84.29. This represents a 54.0% reduction in his non-derivative holdings, from 169,244 shares to 77,807 shares. The sale occurred near the company's 52-week high of $88.12 (current price $79.16 is -10.2% from that peak) and follows a strong 30-day run (+44.0%) and 90-day surge (+98.0%). Despite the material share reduction, the insider retains 40,000 shares via stock options, preserving continued equity exposure. The timing aligns with robust recent price appreciation rather than fundamental deterioration—the company posted +43.9% annual revenue growth, though net income remains negative at -$6.6M on quarterly revenue of $1.6M.

Anterix Chief Legal Officer sold 17,711 shares ($1.4M) on 6/15 at $81.31 avg; retains 9,531 shares plus 42,491 option rights.

Gena L Ashe, Chief Legal Officer & Corporate Secretary, executed 2 separate sales totaling 17,711 (17.7K shares) for $1,440,048.98 ($1.4M) at blended average price of $81.31. The sale reduces her non-derivative holdings by 65.0%, from 27,242 shares to 9,531 shares, while she retains 42,491 shares of stock option rights (Table II derivative securities). The company trades at $79.16, near the upper end of its 52-week range ($17.58–$88.12) and has surged +98.0% over the past 90 days, yet remains unprofitable (full-year net income negative) with quarterly revenue of $1,573,000.00 ($1.6M) and net loss of $6,601,000.00 ($-6.6M). This partial reduction of non-derivative shares by a C-suite insider occurs in the context of significant recent price appreciation but ongoing operational losses.

CEO Scott Lang bought 1,160 shares of Anterix (ATEX) at $21.61 on 12/18, raising stake 16.3% to 8,260 shares amid 47.4% decline from 52-week high.

CEO Lang purchased 1,160 shares at $21.61 on 2025-12-18, increasing his holdings from 7,100 to 8,260 shares (+16.3% net change). This second purchase in 10 days (prior buy on 2025-12-08) comes as the stock trades -47.4% from its 52-week high of $41.99, though it has recovered +5.8% over the past 30 days. At the transaction price of $21.61, the stock was trading below the current price of $22.10, narrowing the gap between insider purchase price and current valuation. Notably, Lang's sole prior ATEX trade with measurable outcomes (Buy on 2025-09-18 at this ticker) posted a +0.3% 90-day return, and his cross-ticker track record across 2 prior buys shows a 100.00% 90-day win rate, though with modest average returns of +0.3%. The company's fundamentals present a paradox: revenue of $1.6M (latest quarter) with annual growth of +43.9%, and a P/E of 4.32, but the company was unprofitable over its most recent full fiscal year despite reporting net income of $53.5M in the latest quarter, suggesting potential quarterly volatility or timing distortions in profitability reporting.

ATEX CEO Lang Scott buys 2,450 shares at $20.41; holdings rise 52.7% to 7,100 shares.

Lang Scott A., President and CEO of Anterix Inc., purchased 2,450 shares at $20.41 on 2025-12-08, increasing his holdings by 52.7% from 4,650 to 7,100 shares. The company is trading at a P/E of 4.23 and recently reported net income of $53.5M against quarterly revenue of $1.6M, though full-year fundamentals remain negative. The stock is currently -48.5% from its 52-week high of $41.99 but has gained 19.1% in the past 30 days. This represents a meaningful accumulation by the CEO at a price materially below recent peaks, though his cross-ticker track record shows 1 prior buy averaging a -4.2% 30-day return, and his prior ATEX buy on 2025-09-18 also returned -4.2% over 30 days. The significance stems from the CEO's substantial increase in personal stake combined with the company's mixed financial profile (strong profitability offset by full-year losses) and current valuation proximity to 52-week lows.

CEO Lang Scott purchases 4,650 shares at $21.28 (stock now -47.0% from 52-week high of $41.99)

Lang Scott A., President and CEO, initiated a personal stake in Anterix by purchasing 4,650 shares at $21.28 on 2025-09-18, with zero prior holdings. The purchase occurs at a significant discount to the 52-week high of $41.99, representing a -47.0% pullback from peak valuations. While the company reported positive net income of $25,180,000.00 in its most recent quarter and strong annual revenue growth of +43.9%, it was unprofitable on a full-year basis, suggesting recent-quarter profitability may not be sustained or reflects a turnaround inflection. At current price of $22.25 (only 4.8% above purchase) and the company trading at P/E of 14.17 with a $417.0M market cap, the CEO's first personal purchase carries mixed signals: it shows executive confidence in recovery prospects, but the limited gain since execution and the divergence between quarterly and full-year profitability warrant scrutiny into whether Q3 results reflect durable margin improvement or cyclical strength.

CFO Timothy Gray bought 50 ATEX shares at $22.07, modest $1.1K purchase amid 47.5% decline from 52-week high.

Gray's purchase of 50 shares for $1,103.50 represents a minimal addition to his 77,022-share position (+0.1%), suggesting a routine rather than conviction-driven transaction. Notably, his prior four trades at ATEX were all sales executed in early May 2024, all of which were followed by positive 90-day returns (ranging +22.0% to +26.6%), indicating poor timing on those exits. The current transaction occurs at $22.07 while the stock sits 47.5% below its 52-week high of $41.99, and 30-day and 90-day momentum show flatness (-0.0%) and weakness (-18.7%) respectively. Absent additional context regarding trade scheduling or plan parameters, the very small purchase size and unfavorable price trajectory relative to the stock's broader decline provide limited signal of insider confidence in near-term recovery.

Director Heard William sold 35,400 shares at blended $39.36 in 6 transactions Feb–Mar 2025, stock now at $32.58.

William Heard, a Director at Anterix Inc., executed 6 separate sales totaling 35,400 shares for $1,393,339.06 across February and March 2025, at an average price of $39.36. The stock has declined 22.8% from its 52-week high and currently trades at $32.58, down 16.4% over the past 30 days. Heard retains substantial holdings of 1.72M shares post-transaction, a reduction of 2.0% from his prior position. The company reported strong recent fundamentals with annual revenue growth of 118.4%, yet was unprofitable over its most recent full fiscal year, creating a disconnect between top-line expansion and profitability—a pattern investors should monitor as the company scales.

Director Fleischhauer buys 3,500 shares of ATEX at $34.19; holds 8,502 shares post-transaction (+70.0% vs prior holdings).

Director Mark Fleischhauer purchased 3,500 shares at $34.19, increasing his holdings by 70.0% to 8,502 shares. The company is unprofitable with annual net income of $-12,766,000.00, though it achieved annual revenue growth of +118.4%. The stock is currently trading at $34.05, approximately 19.3% below its 52-week high of $42.18 and down 9.3% over the past 90 days. This purchase represents a modest absolute dollar commitment ($119,665.00) in a company with a market cap of $633,952,127.55, but the doubling of the director's personal stake in an unprofitable company with high revenue growth warrants monitoring of the company's path to profitability.

Director Daniels buys 2,000 ATEX shares at $32.75; company unprofitable with $-12.8M net income.

Leslie B. Daniels, a director, purchased 2,000 shares of Anterix Inc. at $32.75 on 2024-11-20, establishing an initial position. The purchase occurs in a company context marked by significant operational challenge: Anterix reported a net income of $-12.8M over its most recent full fiscal year, despite posting strong annual revenue growth of +118.4%. At the transaction price of $32.75, the stock was trading -20.1% from its 52-week high of $42.18, though current price of $33.72 is only slightly above the purchase price. The combination of director participation in an open-market purchase alongside steep recent losses and depressed valuation relative to the 52-week range presents a mixed signal that warrants examination of the director's prior transaction history and the company's path to profitability.